ADC Therapeutics (ADCT) Total Liabilities (2019 - 2026)

ADC Therapeutics has disclosed Total Liabilities across 8 years of filings, most recently posting $507.6 million for Q2 2026.

• In Q2 2026, Total Liabilities fell 2.53% year-over-year to $507.6 million; the TTM figure through Jun 2026 stood at $507.6 million (down 2.53% YoY), while the FY2025 annual figure was $509.0 million, down 2.98% from the prior year.
• Total Liabilities came in at $507.6 million for Q2 2026 at ADC Therapeutics, roughly flat from $507.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $527.9 million in Q3 2025 to a low of $405.1 million in Q2 2022.
• Average Total Liabilities over 5 years is $487.1 million, with a median of $507.7 million recorded in 2026.
• The largest YoY upside for Total Liabilities was 156.03% in 2022 against a maximum downside of 8.96% in 2022.
• Over 5 years, Total Liabilities stood at $411.4 million in 2022, then gained by 22.27% to $503.0 million in 2023, then grew by 4.29% to $524.6 million in 2024, then declined by 2.98% to $509.0 million in 2025, then declined by 0.28% to $507.6 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $507.6 million in Q2 2026, $507.9 million in Q1 2026, and $509.0 million in Q4 2025.